Merck wins UK okay for Keytruda in lung cancer after price cut

LONDON, Dec 2 (Reuters) - Britain's healthcare

cost-effectiveness watchdog NICE has recommended use of Merck's

immunotherapy drug Keytruda in certain lung cancer

patients, after the U.S. drugmaker cut the price further for the

state-run health service.

Read more